Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02544-w ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Yusuke Seiki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Dietary Supplements, Zinc, Dysgeusia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although patients with advanced pancreatic cancer (PC) often experience dysgeusia with zinc deficiency during chemotherapy, data on zinc supplementation for dysgeusia and its effects on nutritional status are scarce. We aimed to examine the efficacy of zinc supplementation in patients with advanced PC. METHODS: Thirty-three patients with unresectable PC who presented with dysgeusia and zinc deficiency during chemotherapy and received zinc acetate hydrate between January 2018 and December 2022 were included. We evaluated the changes in serum zinc levels and the improvement in dysgeusia. Among the 26 patients who received zinc supplementation for 12 weeks, we also compared patient characteristics and changes in serum zinc and albumin levels between patients who showed improvement in dysgeusia (effective group) and those who did not (non-effective group). RESULTS: The serum zinc level increased significantly after zinc supplementation (median: 60 µg/dL at baseline, 99.5 µg/dL at 4 weeks, 101 µg/dL at 8 weeks and 101 µg/dL at 12 weeks). The rate of improvement in dysgeusia increased over time (18.2% at 4 weeks, 33.3% at 8 weeks, and 42.4% at 12 weeks). Comparing the effective group and non-effective group revealed that while the median serum albumin level of the effective group did not change, the non-effective group showed a significant decrease from baseline to 12 weeks (3.2 g/dL to 3.0 g/dL, p = 0.03). CONCLUSION: Zinc supplementation significantly increased serum zinc levels, improving dysgeusia. Zinc supplementation might also contribute to maintaining nutritional status in patients with unresectable PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan. ikezawa-ke@oici.jp.
- Department of Dentistry, Osaka International Cancer Institute, Osaka, Japan.
Zitieren
APA
Seiki, Y., Ikezawa, K., Watsuji, K., Urabe, M., Kai, Y., Takada, R., Yamai, T., Mukai, K., Nakabori, T., Uehara, H., Ishibashi, M., & Ohkawa, K. (2024). Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02544-w
Vancouver
Seiki Y, Ikezawa K, Watsuji K, Urabe M, Kai Y, Takada R, et al. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02544-w
BibTeX
@article{Seiki2024,
author = {Seiki, Yusuke and Ikezawa, Kenji and Watsuji, Ko and Urabe, Makiko and Kai, Yugo and Takada, Ryoji and Yamai, Takuo and Mukai, Kaori and Nakabori, Tasuku and Uehara, Hiroyuki and Ishibashi, Miki and Ohkawa, Kazuyoshi},
title = {Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02544-w}
}
EUVIMED